2seventy bio, Inc. Reports Q3 Loss, Lags Revenue Estimates

TARS Stock  USD 52.68  0.23  0.43%   
Slightly above 56% of Tarsus Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Tarsus Pharmaceuticals stock suggests that many investors are alarmed at this time. Tarsus Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Tarsus Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
  
2seventy bio, Inc. delivered earnings and revenue surprises of -28.57 percent and 33.05, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock

Read at zacks.com
zacks News
  

Tarsus Pharmaceuticals Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Tarsus Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Tarsus Pharmaceuticals Fundamental Analysis

We analyze Tarsus Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tarsus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tarsus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Earnings Per Share

Earnings Per Share Comparative Analysis

Tarsus Pharmaceuticals is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.

Tarsus Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tarsus Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Tarsus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Tarsus Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Tarsus Pharmaceuticals Related Equities

GLUEMonte Rosa   6.45   
0%
100.0%
DSGNDesign Therapeutics   4.34   
0%
67.0%
OPTOpthea   3.41   
0%
52.0%
STOKStoke Therapeutics   3.36   
0%
52.0%
ELDNEledon Pharmaceuticals   3.32   
0%
51.0%
ABOSAcumen Pharmaceuticals   2.78   
0%
43.0%
ETONEton Pharmaceuticals   2.36   
0%
36.0%
GNFTGenfit   2.15   
0%
33.0%
TRDAEntrada Therapeutics   1.79   
0%
27.0%
HOWLWerewolf Therapeutics   1.27   
0%
19.0%
PEPGPepGen   0.83   
0%
12.0%
PHVSPharvaris   0.26   
0%
4.0%
CNTBConnect Biopharma   0.11   
0%
1.0%
RLYBRallybio Corp     
1.0%
0%
NUVBNuvation Bio   0.37   
5.0%
0%
NUVLNuvalent   1.16   
17.0%
0%
CNTACentessa Pharmaceuticals   2.22   
34.0%
0%
ALDXAldeyra   2.25   
34.0%
0%
TVTXTravere Therapeutics   2.27   
35.0%
0%
TYRATyra Biosciences   2.43   
37.0%
0%
IKNAIkena Oncology   3.73   
57.0%
0%

Additional Tools for Tarsus Stock Analysis

When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.